Bone from Healthy Individuals and Patients with CKD Expresses the Sodium-Glucose Co-transporter-2 (SGLT2)
Open Access
- 13 March 2026
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 117 (1) , 39
Abstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are used in type 2 diabetes mellitus management, reducing the risk of cardiovascular and renal complications. It has been stated that bone cells do not express the SGLT2 co-transporter; however, the establishment of a direct SGLT2 expression in bone and osteoblast-like cells would provide a significant advance in our understanding of direct SGLT2i effects on bone tissue from patients with metabolic bone diseases, such as chronic kidney disease or osteoporosis. SLC5A2 gene expression was investigated in osteoblast-like and renal HK-2 cells, and in human iliac crest bone samples from healthy individuals and patients with diverse stages of CKD from total RNA by real-time PCR. Additionally, SGLT2 protein qualitative expression was evaluated by Western blot in osteoblast-like cell lysates and by immunohistochemistry in bone samples from apparently healthy individuals and patients with CKD. Statistical significance was set at p < 0.05. SLC5A2 gene expression in osteoblast-like cells is comparable to HK-2 cells. Notably, in human bone samples, SLC5A2 was detected above threshold in both healthy individuals and patients with CKD; thus, absolute quantification of its transcript number of copies was feasible in bone samples for these conditions. SGLT2 protein was detected in osteoblast-like cells. Additionally, this protein was immunodetected in osteocytes embedded in mineralized trabecular and cortical bone samples from healthy subjects and patients with CKD. SLC5A2 gene expression and SGLT2 protein were detected in human osteoblast-like cells and bone from both healthy individuals and patients with CKD. These findings constitute an essential step toward advancing the understanding of effects, if any, of SGLT2 inhibitors on bone tissue from patients with CKD.Keywords
Funding Information
- Universidade Estadual de Campinas (UNICAMP)
This publication has 60 references indexed in Scilit:
- Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney DiseaseJBMR Plus, 2023
- Real‐time quantitative PCR: A tool for absolute and relative quantificationBiochemistry and Molecular Biology Education, 2021
- Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture RiskDiabetes Therapy, 2019
- The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetesBone, 2017
- SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male miceBone, 2016
- How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessmentsBiomolecular Detection and Quantification, 2015
- Identification of valid housekeeping genes for quantitative RT-PCR analysis of cardiosphere-derived cells preconditioned under hypoxia or with prolyl-4-hydroxylase inhibitorsMolecular Biology Reports, 2011
- Usefulness of a quick decalcification of bone sections embedded in methyl metacrylate: an improved method for immunohistochemistryJournal of Bone and Mineral Metabolism, 2008
- Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-κb ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolismBone, 2004
- Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)Journal of Cellular Biochemistry, 2003